Abstract 417P
Background
CDK4/6i with endocrine therapy (ET) still represents the best 1st-line (1L) choice for HR+/HER2- MBC pts. At progression, the optimal subsequent strategy remains an open question. The HERMIONE-13 study aims to describe the efficacy of 2L choices in terms of Progression Free Survival (PFS) and Clinical Benefit Rate (CBR), in HR+/HER2- MBC pts relapsed after CDK 4/6i + ET.
Methods
HERMIONE-13 is a retrospective and prospective multicentric observational trial conducted in 15 Centers in Italy. Data of pts with at least one disease’ revaluation during 2L therapy are being collected from January 2016 until January 2024. Here we present the first data of pts enrolled until December 2020.
Results
Among 114 pts enrolled, 16 (14%) were primary endocrine resistant, 70 (61.4%) had visceral metastases and 64 (56%) have received Palbociclib. Median 1L PFS (mPFS) was 11 months (mo) (interquartile range (IQR): 5-18). The 2L preferred choice was a chemotherapy (CHT)-based regimen (69.3%), with a predominance of single agent Capecitabine (22,2%); ET + target therapy (TT) was chosen in 16.7% of pts and ET monotherapy in 14%. An ET-based treatment was more frequently chosen for pts with a PFS≥6 mo to previous CDK4/6i (35.4%), with respect to those with a PFS<6mo (13.3%) (P=0.024). A significant improvement in CBR, defined as absence of disease progression at 1st reassessment, was observed with CHT versus ET (20%, P=0.047). Among CHT treatments, a metronomic schedule of oral Capecitabine +/- Vinorelbine +/-Cyclophosphamide was used in 22.8% of pts, with a mPFS of 6 mo. Table: 417P
N° of pts (%) | 2L mPFS,in mo (IQR) | CBR 2L (%) | |
All treatment | 114 | 6 (3-10) | 55 (48.2) |
ET +/- TT | 35 (30.7) | 5 (3-7) | 12 (34.3) |
CHT +/- TT | 79 (69.3) | 6 (4-12) | 43 (54.4) |
Non-metronomic CHT | 61 (77.2) | 6 (3-11) | 32 (52.5) |
Metronomic CHT | 18 (22.8) | 6 (4-12) | 11 (61.1) |
Conclusions
In Italy, the preferred 2L treatment after CDK 4/6i remains CHT, especially with single-agent or metronomic schedule. mPFSs of 2L choices are very similar each other, around 6 mo. Further efforts to understand the type of resistance to CDK4/6i are warranted to better select 2L therapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
University of Milan Bicocca.
Funding
Has not received any funding.
Disclosure
O. Garrone: Financial Interests, Advisory Board: Eisai, MSD, Daiichi Sankyo, Gilead; Financial Interests, Other, Honoraria: Novartis, Pfizer, Lilly. M. Mazzotta: Financial Interests, Advisory Board: Roche, AstraZeneca. P. Vici: Financial Interests, Personal, Advisory Board: Novartis, Eisai, Pfizer, Lilly; Financial Interests, Institutional, Local PI, multicentric trial (Persevera): Roche; Financial Interests, Institutional, Local PI, multicentric study (LIDERA): Roche; Financial Interests, Institutional, Local PI, EPIK B2: Novartis. All other authors have declared no conflicts of interest.
Resources from the same session
445P - Tyrosine kinase inhibitors (TKIs) in HER2-positive metastatic breast cancer after trastuzumab emtansine (T-DM1) failure: A multicenter real-world study
Presenter: Chunxiao Sun
Session: Poster session 03